Compare PAMT & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAMT | AMRN |
|---|---|---|
| Founded | 1980 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.4M | 287.9M |
| IPO Year | 1995 | 1998 |
| Metric | PAMT | AMRN |
|---|---|---|
| Price | $10.89 | $11.79 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 22.9K | ★ 59.4K |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $437,838,000.00 | $181,104,000.00 |
| Revenue This Year | $17.76 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.15 | ★ 39.22 |
| 52 Week Low | $7.15 | $11.25 |
| 52 Week High | $17.75 | $20.57 |
| Indicator | PAMT | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 37.79 |
| Support Level | $9.39 | N/A |
| Resistance Level | $11.00 | $14.50 |
| Average True Range (ATR) | 0.91 | 0.34 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 19.86 | 55.34 |
PAMT Corp is a holding company that is engaged in providing truckload dry van carrier services transporting general commodities throughout the continental United States and Mexico, as well as in certain Canadian provinces. Its freight consists of automotive parts, expedited goods, consumer goods, such as general retail store merchandise, and manufactured goods, such as heating and air conditioning units. It has one reportable segment being motor carrier.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.